Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity

NCT02751931 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
91
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Astellas Pharma Europe B.V.